The price of Lineage Cell Therapeutics Inc (AMEX:LCTX) shares last traded on Wall Street rose 5.42% to $0.61.
LCTX stock price is now -29.12% away from the 50-day moving average and -39.80% away from the 200-day moving average. The market capitalization of the company currently stands at $114.24M.
With the price target of $4, Craig Hallum recently initiated with Buy rating for Lineage Cell Therapeutics Inc (AMEX: LCTX). On November 02, 2022, Robert W. Baird recently initiated its ‘Outperform’ rating on the stock quoting a target price of $5, while ‘B. Riley Securities’ rates the stock as ‘Buy’
In other news, Howe Jill Ann, Chief Financial Officer bought 15,000 shares of the company’s stock on Nov 26 ’24. The stock was bought for $8,850 at an average price of $0.59. Upon completion of the transaction, the Chief Financial Officer now directly owns 25,500 shares in the company, valued at $15555.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 26 ’24, General Counsel Samuel George A. III bought 15,000 shares of the business’s stock. A total of $9,000 was incurred on buying the stock at an average price of $0.60. This leaves the insider owning 22,184 shares of the company worth $13532.24. A total of 0.62% of the company’s stock is owned by insiders.
During the past 12 months, Lineage Cell Therapeutics Inc has had a low of $0.50 and a high of $1.61. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 2.48, and a quick ratio of 2.48. The fifty day moving average price for LCTX is $0.86 and a two-hundred day moving average price translates $1.00755 for the stock.
The latest earnings results from Lineage Cell Therapeutics Inc (AMEX: LCTX) was released for 2024-06-30. The net profit margin was -230.66% and return on equity was -29.95% for LCTX. The company reported revenue of $3.78 million for the quarter, compared to $1.25 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 203.29 percent.
